63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer

Background

Eribulin, a novel anti-tubulin agent, is a preferred treatment for patients (pts) with metastatic breast cancer (mBC) who have been pretreated with anthracycline and/or taxane-based therapy. Preclinical data suggest a potential synergistic effect of eribulin and platinum. However, clinical data on the combination for mBC are lacking. We evaluated eribulin plus platinum in pts with mBC.

Methods

This multi-center, real-world cohort study included pts with pre-treated metastatic triple- negative breast cancer (TNBC) or endocrine-refractory hormone receptor (HR) -positive, HER2 -negative mBC who received eribulin plus carboplatin (ErCb). Eribulin (1.4 mg/m²) and carboplatin (target AUC=2) were administered intravenously on days 1 and 8 of 21-day cycles. Progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and adverse events (AEs) were evaluated.

Results

From March 2022 to August 2023, 19 pts with TNBC and 11 with HR+HER2- mBC were included. Of the 19 pts with TNBC, 8 had an initial diagnosis of HR+HER2- disease. All 30 pts were female, with a median (range) age of 46 (31–60) years and had received a median of 2 (1–6) prior lines of therapy. Visceral metastases were present in 22 pts (73.3%). Best overall response, ORR, DCR, and PFS are shown in the table. Median overall survival was not reached. After a median of 6 cycles (range, 2–8) of ErCb, the most common grade 3–4 AEs were neutropenia (40.0%), leukopenia (23.3%), febrile neutropenia (10.0%), and anemia (3.3%). No grade 3–4 non-hematological AEs were observed. Table: 63P

Conclusions

In this cohort of pts with heavily pre-treated HER2- mBC, ErCb demonstrated promising efficacy and a manageable safety profile. Further studies exploring this combination in earlier lines of treatment for mBC are warranted.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.